ASTH News & Events

Sees FY26 adjusted EBITDA $250M-$280M.

Reports Q4 revenue $950.5M, consensus $930.46M. "Astrana delivered record revenue, adjusted EBITDA, and free cash flow in 2025, demonstrating the strength and predictability of our fully delegated, payer-agnostic care model and AI-enabled technology platform in a dynamic operating environment," said Brandon Sim, President and CEO of Astrana Health. "Our disciplined approach to risk, strong physician alignment, and technology-enabled clinical infrastructure drove consistent performance while creating measurable value for patients through improved outcomes, greater access, and lower total cost of care. As we move through 2026, with Prospect Health integration ahead of schedule, we are confident in our ability to deliver on guidance that reflects approximately 24% revenue growth and 29% adjusted EBITDA growth at the midpoint."

Sees Q1 adjusted EBITDA $60M-$70M.

The Board of Directors has increased the maximum aggregate amount of shares of the company's common stock that may be purchased under the company's existing share repurchase program from $50M to $100M.